ORLANDO, Fla. — Exagamglogene autotemcel (exa-cel, Casgevy), a CRISPR/Cas9 gene-editing therapy, showed efficacy in children aged 5-11 years with transfusion-dependent beta-thalassemia (TDT) or sickle ...

Court official dismisses Justice Department's misconduct complaint against a federal judge in DC Mount Rainier summit drops 20 feet, climate study finds Former House Speaker McCarthy warns Marjorie ...

Throughout medical school and into residency, Edward “Donnell” Ivy, MD, MPH, wanted to become a pediatrician, so he could help children avoid the suffering he’d experienced as a child with sickle cell ...

LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...

Ritwik is a passionate gamer who has a soft spot for JRPGs. He's been writing about all things gaming for six years and counting. No matter how great a title's gameplay may be, there's always the ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from the American Society of Hematology. The articles in the series are ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

LMP Capital and Income Fund offers an 8% dividend yield, focusing on income through diverse investments in MLPs, REITs, and common stocks. SCD's strategy includes a mix of energy and tech stocks, ...